Prostate cancer
ProstACT-Global-203
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177 Lu) rosopatamab tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously after Androgen Receptor Pathway Inhibitor Treatment
Trial overview
Clinical Area
Theranostics
Disease / Condition
Prostate cancer
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)